Dr. Patrick M. Boland, MD

Dr. Boland practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Boland's NPI, 1982870333, was assigned on May 6, 2008. Dr. Boland graduated from Sidney Kimmel Medical College in 2006. Dr. Boland holds New Jersey license 25MA10675000.

Dr. Boland's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Boland also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Boland's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Dr. Boland is also affiliated with Robert Wood Johnson University Hospital Somerset. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Dr. Boland to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Boland practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Boland's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Boland is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Boland's licenses on file in 4 states: New Jersey, New York, Pennsylvania and Massachusetts.

Dmand AI lists neuropathy and non-alzheimer's dementia (chronic) among the conditions Dr. Boland treats.

CMS data shows 370 Medicare services from Dr. Boland across 5 procedure codes in 2024, for 139 Medicare patients. Medicare paid $32,124 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 139 Medicare patients who saw Dr. Boland in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Boland's median patient age at 68, with 49% women.

In 2024, Dr. Boland wrote 347 Medicare Part D claims for 77 patients. 85% of them were for generic drugs. CMS names the drug for 156 of them, across 9 drugs with 11 or more claims each, at $13,611 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Boland for performance year 2024, reported as part of a group. Dr. Boland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Boland as offering telehealth.

Dmand AI links 58 papers to Dr. Boland, published from 2007 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Adenocarcinoma. Dr. Boland has published most often in J Gastrointest Oncol. Dr. Boland's most frequent co-authors are Steven J. Nurkin, MD, Emmanuel M. Gabriel, MD and Wen Wee Ma, MD.

Dmand AI links Dr. Boland to 15 clinical trials, 8 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Colonic Neoplasms. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 28 general payments to Dr. Boland from 7 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 77% of the total. Bristol-Myers Squibb Company paid the most, $4,766. It also lists 1 research payment totaling $4,350 in 2025.

Dr. Boland graduated from Sidney Kimmel Medical College in 2006. Dr. Boland is a member of ASCO.

Dr. Boland is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.